お知らせ • Apr 20
10x Genomics Introduces Atera Platform
10x Genomics, Inc. announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale. Atera is engineered to enable large-scale whole-transcriptome spatial studies across both fresh-frozen and FFPE tissue, supporting diverse applications in both discovery and translational research. Atera removes these limitations, enabling the complete measurement of biology, in its native context at single-cell resolution and at scale, without compromise. Atera marks a fundamental shift in how biology is analyzed and understood. Carl June's Opening Plenary session at the American Association for Cancer Research Annual Meeting 2026 will include data from the June Lab's early access samples analyzed on Atera. Data presented at AACR by the German Cancer Research Center will highlight Atera's ability to challenge prevailing assumptions and uncover cancer biology not accessible with legacy approaches. Researchers distinguished multiple malignant and stem cell states, across disease stages, within a single colorectal tumor sample and mapped how these populations interact with the surrounding immune microenvironment. Tumors previously characterized as having limited or low immune infiltration were found to harbor active and diverse immune cell populations, revealing a more complex immune landscape that could inform future therapeutic strategies and drug development. Leading life sciences organizations and research institutions have already committed to utilizing Atera at scale, underscoring strong demand for high-throughput, high-sensitivity spatial analysis across both whole-transcriptome and targeted applications. As the Human Cell Atlas continues its mission to map every cell type in the human body, its success will require uncompromised spatial biology at scale, and Atera will enable the consortium to achieve its next set of ambitious goals. Whole-transcriptome spatial transcriptomics transforms tissues into living maps, enabling scientists to visualize complex cellular interactions in disease, uncover hidden mechanisms in clinical specimens and identify new therapeutic targets. Global service providers are moving to adopt Atera to support the next generation of spatial studies. Macrogen, a global Contract Research Organization, along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera instruments, becoming the first global service provider to adopt the platform. This investment reflects growing demand for high-throughput, uncompromised spatial analysis in biopharma and translational research, and positions Macrogen to support large-scale spatial programs. Atera builds on the momentum and leadership in spatial biology established by Xenium, which remains the trusted solution for generating spatial data. Bioptimus, a France-based AI biotech company, recently announced its partnership with 10x to build one of the world's spatial datasets, STELA, a global initiative to power their multimodal AI platform, M-Optimus. The data will provide the cornerstone of the AI-driven biology and drug discovery engine at Bioptimus. Bioptimus begins with Xenium to generate high-quality spatial data immediately, with plans to expand to Atera in 2027 as increased throughput enables the program to scale toward its full ambition. Atera reflects a first-principles approach to solving a core challenge in biology, which is how to measure complex systems without limitations. The result is a platform that delivers whole-transcriptome spatial data with single-cell sensitivity at scale. The Atera platform will substantially expand the scope of questions that can be addressed in spatial biology. To harness the scale of insight generated by Atera's whole-transcriptome studies, 10x is introducing a new cloud analysis platform to securely store, analyze, visualize and collaborate on spatial datasets. Building on the foundation of Xenium Explorer, the new platform brings intuitive visualization into the web and pairs it with GPU-accelerated analysis, empowering biologists to bridge the gap between raw data and insight in minutes instead of hours. Researchers maintain full control over their data and workflows with Atera routing results to 10x Cloud, customer-managed cloud or on-premise data storage. Broad accessibility to Atera is critical to enabling biological impact. To ensure researchers can access the new platform, regardless of their project size or infrastructure, 10x has launched Catalyst Research Services, enabling direct submission of samples for whole-transcriptome spatial analysis. The program offers flexible access packages, with pre-booking now available and sample processing beginning alongside Atera's commercial availability. Atera will be introduced at the AACR Annual Meeting 2026, where 10x will host in-person and digital launch events that include early data generated on the platform; additionally, the company will host an Exhibitor Spotlight Presentation on Atera. Exhibitor Spotlight Presentation: 10x Genomics will introduce Atera, including a presentation from the German Cancer Research Center with data generated on the platform, on April 19 at 1:30 PM PT in Spotlight Theater C, Sails Pavilion, San Diego Convention Center. Poster #7116: Atera enables clinical-scale spatial studies by overcoming limitations in cost, workflow and performance, generating high-resolution, low-noise datasets optimized for AI-driven biomarker discovery and early cancer detection. Poster #6216: Whole-transcriptome spatial analysis with Atera reveals TME remodeling genes and mitotic signaling at the tumor invasive front, providing new mechanistic insight into tumor progression and immune evasion in cervical and breast cancer. Pre-orders for Atera are now open. The platform is expected to begin shipping in the second half of 2026. 10x Genomics contemplated the launch of Atera when it provided its full-year 2026 financial outlook in February. Additional details on the platform can be found in the Atera media kit.
